22.05.2014 • NewsDede Willamsjoint ventureJV

Venezuela in First Shale Gas Exploration Project

Venezuela plans to begin its first shale gas exploration campaign in western Lake Maracaibo as part of a joint venture with Brazil's state-run Petrobras.

"We've approved the first explorations for shale gas," energy minister Rafael Ramirez said on May 21. Ramirez is also the head of Venezuelan state oil company PDVSA.

The Petrowayu joint venture will run the project.

PDVSA will have a 60% stake in the exploration company, while Petrobras will have 36% and U.S.-based Williams 4%

The minister did not say when exploration would start, nor how much PDVSA and its partners would likely spend.

PDVSA also has run initial tests for shale gas at La Guajira, in the hope of discovering significant reserves of unconventional resources.

The OPEC nation has vast reserves of conventional gas, but several offshore gas projects with foreign partners are still waiting to start output.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.